Suresh (“Sam”) V. Muppalla
About Suresh (“Sam”) V. Muppalla
Suresh (“Sam”) V. Muppalla, age 55, served as President of Tissue Health Plus, LLC (“THP”) since April 2023 and became THP’s President & CEO in April 2025; he holds a Bachelor’s degree in Computer Science & Engineering from College of Engineering, Trivandrum . His background includes CEO of American Medical Technologies (built into the nation’s largest Skilled Nursing wound care services provider), growth leadership roles at Edifecs and Portico, and senior positions at McKesson, Comcast, and Deloitte; he is a Partner at The Catalyst Group and serves on multiple boards including Smartlix . Company performance context: SMTI’s cumulative TSR for a $100 investment was $91.18 (2022), $82.36 (2023), and $112.35 (2024) ; net revenue grew 25% year-over-year to $75.6M for the first nine months of 2025, and Adjusted EBITDA rose to $12.3M from $5.1M in the comparable 2024 period . In November 2025 the Company discontinued THP operations, classifying THP as discontinued operations, which materially affects the THP business overseen by Muppalla .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Tissue Health Plus, LLC (SMTI subsidiary) | President; later President & CEO | President: Apr 2023–Apr 2025; President & CEO since Apr 2025; THP discontinued mid-Sep 2025 | Led THP platform development and operations within SMTI; the segment was discontinued in 2025 |
| American Medical Technologies | Chief Executive Officer | Until 2021 | Built AMT into the nation’s largest Skilled Nursing wound care services provider |
| Edifecs | Growth strategy leadership | Not disclosed | Led growth strategies in health IT |
| Portico | Growth strategy leadership | Not disclosed | Led growth strategies in health IT |
| McKesson; Comcast; Deloitte | Senior leadership positions (US and Europe) | Not disclosed | Senior operating and leadership roles across large enterprises |
| Private Equity advisorship | Advisor to PE firms | 2021–2023 | Advised PE firms on growth strategy; transitional role pre-THP |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| The Catalyst Group, Inc. | Partner | Not disclosed | Provides growth capital and strategic advisory to private companies |
| Smartlix (Healthcare Workforce Platform) | Board member | Not disclosed | External governance and industry engagement |
Fixed Compensation
| Component | Company Program (SMTI) | Muppalla-Specific Disclosure |
|---|---|---|
| Base salary | Executive compensation generally includes base salary | Not disclosed in proxy/8-Ks for Muppalla (not a named executive officer) |
| Target annual bonus | Annual cash bonus determined by Board, based on company and individual performance | Not disclosed for Muppalla |
| Equity awards | Restricted stock grants are used; company currently does not grant options/SARs | Not disclosed for Muppalla |
| Award timing policy | Equity award timing policy disclosed (no option-like instruments currently) | Not applicable to Muppalla absent disclosed awards |
Performance Compensation
- SMTI states executive bonuses are discretionary and based on Company and individual performance; specific performance metrics, weights, and payouts are not disclosed for Muppalla (he is not among the named executive officers with detailed tables) .
Equity Ownership & Alignment
| Item | Disclosure | Details |
|---|---|---|
| Beneficial ownership | Not disclosed for Muppalla | The proxy’s beneficial ownership table covers directors, director nominees, and named executive officers; Muppalla is not included in those categories . |
| Hedging/pledging | Prohibited without prior approval | Insider trading policy prohibits hedging, short sales, options trading, margin accounts, and pledging company stock without advance approval of the CEO and CFO . |
| Stock ownership guidelines | Not disclosed | No executive ownership multiple-of-salary policy is disclosed in the proxy for executives; director equity retainer is disclosed separately . |
Employment Terms
| Item | Disclosure | Terms |
|---|---|---|
| THP role status | Disclosed | President since Apr 2023; President & CEO since Apr 2025; THP operations discontinued mid-Sep 2025 with wind-down through year-end . |
| Employment agreement | No agreement disclosed for Muppalla | No 8-K Item 5.02 or proxy exhibit detailing Muppalla’s specific employment terms found. |
| Change-of-control (equity) | Disclosed at plan level | Under both the 2014 and 2024 Plans, upon a Change in Control, all restricted stock awards become fully vested; Change in Control definitions include mergers (<50% post-merger voting power), sale/transfer of substantially all assets, and liquidation/dissolution (plan-specific differences) . |
| Clawbacks, non-compete | Not disclosed for Muppalla | No specific clawback or restrictive covenant terms disclosed for Muppalla; company-level insider policy noted above . |
Company Performance Context
| Metric | 9M 2024 | 9M 2025 |
|---|---|---|
| Net Revenue ($USD Millions) | $60.4 | $75.6 |
| Adjusted EBITDA ($USD Millions) | $5.1 | $12.3 |
| Year | Cumulative TSR Value of $100 Investment ($) |
|---|---|
| 2022 | 91.18 |
| 2023 | 82.36 |
| 2024 | 112.35 |
Investment Implications
- Compensation alignment visibility is limited: Muppalla is not a named executive officer; base salary, bonus targets, equity grant quantities, and vesting schedules are not disclosed, which constrains pay‑for‑performance analysis and modeling of future selling pressure .
- Equity alignment risk appears mitigated by policy: SMTI prohibits hedging and pledging without prior approval, reducing misalignment risks; however, absent disclosure of his personal holdings, it’s not possible to assess “skin in the game,” vesting overhang, or pledge exposure for Muppalla .
- Change-of-control accelerators could influence incentives: Restricted stock awards fully vest on change of control under the 2014/2024 Plans, which may encourage transaction receptivity; without award detail for Muppalla, the magnitude of this lever cannot be quantified .
- Execution/retention risk from THP discontinuation: SMTI ceased THP operations in mid‑September 2025; given Muppalla’s THP leadership, role continuity and severance/change-of-control economics for him are not disclosed, representing a tangible retention/transition risk for investors to monitor .
- Track record suggests operational growth capability in wound care and health IT; his prior AMT scaling and HIT growth roles are additive for strategy and commercial execution, but lack of current, disclosed incentive metrics (e.g., revenue, EBITDA, TSR hurdles) limits predictive confidence on incentive-driven performance .